Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Oct. 02, 2011

Schedule of Changes in Carrying Amount of Goodwill [Table Text Block]

The changes in the carrying amount of goodwill for the nine months ended October 2, 2011, follow:

(millions of dollars)	Primary Care	Specialty Care and Oncology	Established Products and Emerging Markets	Animal Health and Consumer Healthcare		Nutrition		To be allocated(a)			Total
	$									$
Balance, December 31, 2010				$	2,449	$	496	$	40,983	$	43,928
Additions(b)					—		—		825		825
Other(c)					15		11		630		656
Balance, October 2, 2011	$			$	2,464	$	507	$	42,438	$	45,409

(a) The amount to be allocated includes the former Biopharmaceutical goodwill (see below), as well as newly acquired goodwill, substantially all from our acquisition of King, for which the allocation to reporting units is pending (see Note 3. Acquisition of King Pharmaceuticals, Inc. for additional information).

(b) Substantially all of the amount relates to our acquisition of King and is subject to change until we complete the recording of the assets acquired and liabilities assumed from King (see Note 3. Acquisition of King Pharmaceuticals, Inc.). The allocation of King goodwill among our reporting units has not yet been completed, but will be completed within one year of the acquisition date.

(c) Primarily reflects the impact of foreign exchange.

Schedule of Identifiable Intangible Assets [Table Text Block]

The components of identifiable intangible assets follow:

	Oct. 2, 2011							December 31, 2010
(millions of dollars)	Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization
Finite-lived intangible assets:
Developed technology rights	$	71,288	$	(30,932	)	$	40,356	$	68,432	$	(26,223	)	$	42,209
Brands		1,693		(569	)		1,124		1,626		(607	)		1,019
License agreements		589		(284	)		305		637		(248	)		389
Trademarks and other		558		(441	)		117		533		(324	)		209
Total amortized finite-lived intangible assets		74,128		(32,226	)		41,902		71,228		(27,402	)		43,826
Indefinite-lived intangible assets:
Brands		10,291		—			10,291		10,219		—			10,219
In-process research and development		3,332		—			3,332		3,438		—			3,438
Trademarks		72		—			72		72		—			72
Total indefinite-lived intangible assets		13,695		—			13,695		13,729		—			13,729
Total identifiable intangible assets(a)	$	87,823	$	(32,226	)	$	55,597	$	84,957	$	(27,402	)	$	57,555

(a) The decrease is primarily related to amortization as well as impairment charges (see Note 6. Other (Income)/Deductions—Net), partially offset by the assets acquired as part of the acquisition of King (see Note 3. Acquisition of King Pharmaceuticals, Inc.) and the impact of foreign exchange.